Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity

Vaccine

Volumn 33, Issue S2, 2015, Pages B21-B28

  Kamphorst, Alice O ^a   Araki, Koichi ^a   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; CTLA 4; IL 2; MTOR; PD 1; Treg cells

Indexed keywords

CD8 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PROGRAMMED DEATH 1 RECEPTOR; TARGET OF RAPAMYCIN KINASE;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INFECTION; LONG TERM MEMORY; MEMORY T LYMPHOCYTE; METASTATIC MELANOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VACCINATION; ADAPTIVE IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM;

ADAPTIVE IMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOMODULATION; INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES;

EID: 84929868317     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.12.082     Document Type: Review

References (120)

1. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
2. Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med 2013, 19:1597-1608.
3. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
4. Kim P.S., Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010, 22:223-230.
5. Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013, 13:227-242.
6. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009, 10:29-37.
7. Pentcheva-Hoang T., Corse E., Allison J.P. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009, 229:67-87.
8. Kearney E.R., Walunas T.L., Karr R.W., Morton P.A., Loh D.Y., Bluestone J.A., et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 1995, 155:1032-1036.
9. McCoy K., Camberis M., Gros G.L. Protective immunity to nematode infection is induced by CTLA-4 blockade. J Exp Med 1997, 186:183-187.
10. Pedicord V.A., Montalvo W., Leiner I.M., Allison J.P. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A 2011, 108:266-271.
11. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
12. Wing K., Yamaguchi T., Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011, 32:428-433.
13. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell extrinsic function of CTLA-4. Science 2011, 332:600-603.
14. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
15. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
16. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
17. Friedline R.H., Brown D.S., Nguyen H., Kornfeld H., Lee J., Zhang Y., et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009, 206:421-434.
18. Schubert D., Bode C., Kenefeck R., Hou T.Z., Wing J.B., Kennedy A., et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014, 20:1410-1416.
19. Bulliard Y., Jolicoeur R., Windman M., Rue S.M., Ettenberg S., Knee D.A., et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013, 210:1685-1693.
20. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013, 1:32-42.
21. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210:1695-1710.
22. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725.
23. Wolchok J.D., Hodi F.S., Weber J.S., Allison J.P., Urba W.J., Robert C., et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013, 1291:1-13.
24. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
25. Noman M.Z., Desantis G., Janji B., Hasmim M., Karray S., Dessen P., et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014, 211:781-790.
26. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008, 8:467-477.
27. Mueller S.N., Vanguri V.K., Ha S.J., West E.E., Keir M.E., Glickman J.N., et al. PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest 2010, 120:2508-2515.
28. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99:12293-12297.
29. Channappanavar R., Twardy B.S., Suvas S. Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection. PLoS ONE 2012, 7:e39757.
30. Erickson J.J., Gilchuk P., Hastings A.K., Tollefson S.J., Johnson M., Downing M.B., et al. Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J Clin Invest 2012, 122:2967-2982.
31. Finnefrock A.C., Tang A., Li F., Freed D.C., Feng M., Cox K.S., et al. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol 2009, 182:980-987.
32. Blattman J.N., Wherry E.J., Ha S.J., van der Most R.G., Ahmed R. Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J Virol 2009, 83:4386-4394.
33. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
34. Wherry E.J. T cell exhaustion. Nat Immunol 2011, 12:492-499.
35. Shin H., Wherry E.J. CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol 2007, 19:408-415.
36. Fourcade J., Kudela P., Sun Z., Shen H., Land S.R., Lenzner D., et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009, 182:5240-5249.
37. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
38. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
39. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006, 80:11398-11403.
40. Trautmann L., Janbazian L., Chomont N., Said E.A., Gimmig S., Bessette B., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
41. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203:2281-2292.
42. Gardiner D., Lalezari J., Lawitz E., DiMicco M., Ghalib R., Reddy K.R., et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE 2013, 8:e63818.
43. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
44. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
45. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
46. Powles T., Vogelzang N.J., Fine G.D., Eder J.P., Braiteh F.S., Loriot Y., et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol 2014, 32. abstr 5011.
47. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
48. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
49. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
50. Jin H.T., Anderson A.C., Tan W.G., West E.E., Ha S.J., Araki K., et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010, 107:14733-14738.
51. Butler N.S., Moebius J., Pewe L.L., Traore B., Doumbo O.K., Tygrett L.T., et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 2012, 13:188-195.
52. Ha S.J., West E.E., Araki K., Smith K.A., Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 2008, 223:317-333.
53. Kamphorst A.O., Ahmed R. Manipulating the PD-1 pathway to improve immunity. Curr Opin Immunol 2013, 25:381-388.
54. Ha S.J., Mueller S.N., Wherry E.J., Barber D.L., Aubert R.D., Sharpe A.H., et al. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008, 205:543-555.
55. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366.
56. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60:2444-2448.
57. Li B., VanRoey M., Wang C., Chen T.H., Korman A., Jooss K. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor - secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009, 15:1623-1634.
58. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
59. Cox M.A., Kahan S.M., Zajac A.J. Anti-viral CD8 T cells and the cytokines that they love. Virology 2013, 435:157-169.
60. Curtsinger J.M., Mescher M.F. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 2010, 22:333-340.
61. O'Shea J.J., Paul W.E. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010, 327:1098-1102.
62. Toe J.G., Pellegrini M., Mak T.W. Promoting immunity during chronic infection - the therapeutic potential of common gamma-chain cytokines. Mol Immunol 2013, 56:38-47.
63. Katzman S.D., Hoyer K.K., Dooms H., Gratz I.K., Rosenblum M.D., Paw J.S., et al. Opposing functions of IL-2 and IL-7 in the regulation of immune responses. Cytokine 2011, 56:116-121.
64. West E.E., Jin H.T., Rasheed A.U., Penaloza-Macmaster P., Ha S.J., Tan W.G., et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest 2013, 123:2604-2615.
65. Sim G.C., Martin-Orozco N., Jin L., Yang Y., Wu S., Washington E., et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014, 124:99-110.
66. Blattman J.N., Grayson J.M., Wherry E.J., Kaech S.M., Smith K.A., Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003, 9:540-547.
67. Kalia V., Sarkar S., Subramaniam S., Haining W.N., Smith K.A., Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 2010, 32:91-103.
68. Pipkin M.E., Sacks J.A., Cruz-Guilloty F., Lichtenheld M.G., Bevan M.J., Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010, 32:79-90.
69. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987, 316:889-897.
70. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014, 192:5451-5458.
71. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127.
72. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
73. Paley M.A., Kroy D.C., Odorizzi P.M., Johnnidis J.B., Dolfi D.V., Barnett B.E., et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012, 338:1220-1225.
74. Kaech S.M., Tan J.T., Wherry E.J., Konieczny B.T., Surh C.D., Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003, 4:1191-1198.
75. Maker A.V., Phan G.Q., Attia P., Yang J.C., Sherry R.M., Topalian S.L., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005, 12:1005-1016.
76. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007, 8:191-197.
77. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
78. Yamaguchi T., Wing J.B., Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol 2011, 23:424-430.
79. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
80. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564.
81. Toka F.N., Suvas S., Rouse B.T. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. J Virol 2004, 78:13082-13089.
82. Moore A.C., Gallimore A., Draper S.J., Watkins K.R., Gilbert S.C., Hill A.V. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J Immunol 2005, 175:7264-7273.
83. Pace L., Tempez A., Arnold-Schrauf C., Lemaitre F., Bousso P., Fetler L., et al. Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory. Science 2012, 338:532-536.
84. Lund J.M., Hsing L., Pham T.T., Rudensky A.Y. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008, 320:1220-1224.
85. Nishikawa H., Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014, 27:1-7.
86. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
87. Belkaid Y., Tarbell K. Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol 2009, 27:551-589.
88. Li S., Gowans E.J., Chougnet C., Plebanski M., Dittmer U. Natural regulatory T cells and persistent viral infection. J Virol 2008, 82:21-30.
89. Facciabene A., Motz G.T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012, 72:2162-2171.
90. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
91. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
92. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:18538-18543.
93. Awwad M., North R.J. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J Exp Med 1988, 168:2193-2206.
94. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59:3128-3133.
95. Lahl K., Loddenkemper C., Drouin C., Freyer J., Arnason J., Eberl G., et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007, 204:57-63.
96. Teng M.W., Ngiow S.F., von Scheidt B., McLaughlin N., Sparwasser T., Smyth M.J. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 2010, 70:7800-7809.
97. Klages K., Mayer C.T., Lahl K., Loddenkemper C., Teng M.W., Ngiow S.F., et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010, 70:7788-7799.
98. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194:823-832.
99. Bos P.D., Plitas G., Rudra D., Lee S.Y., Rudensky A.Y. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhance radiotherapy. J Exp Med 2013, 210:2435-2466.
100. Komatsu N., Hori S. Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc Natl Acad Sci U S A 2007, 104:8959-8964.
101. Drake C.G. Combination immunotherapy approaches. Ann Oncol 2012, 23(Suppl. 8):viii41-viii46.
102. Penaloza-MacMaster P., Kamphorst A.O., Wieland A., Araki K., Iyer S.S., West E.E., et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med 2014, 211:1905-1918.
103. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
104. Le D.T., Jaffee E.M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012, 72:3439-3444.
105. Sugiyama D., Nishikawa H., Maeda Y., Nishioka M., Tanemura A., Katayama I., et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013, 110:17945-17950.
106. Delgoffe G.M., Woo S.R., Turnis M.E., Gravano D.M., Guy C., Overacre A.E., et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 2013, 501:252-256.
107. Hansen W., Hutzler M., Abel S., Alter C., Stockmann C., Kliche S., et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med 2012, 209:2001-2016.
108. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
109. Shimobayashi M., Hall M.N. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 2014, 15:155-162.
110. Araki K., Turner A.P., Shaffer V.O., Gangappa S., Keller S.A., Bachmann M.F., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
111. Bassett J.D., Swift S.L., VanSeggelen H., Hammill J.A., McGray A.J., Evelegh C., et al. Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines. Mol Ther 2012, 20:860-869.
112. Rao R.R., Li Q., Odunsi K., Shrikant P.A. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and eomesodermin. Immunity 2010, 32:67-78.
113. Pearce E.L., Walsh M.C., Cejas P.J., Harms G.M., Shen H., Wang L.S., et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460:103-107.
114. Ferrer I.R., Wagener M.E., Robertson J.M., Turner A.P., Araki K., Ahmed R., et al. Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol 2010, 185:2004-2008.
115. Xu X., Ye L., Araki K., Ahmed R. mTOR, linking metabolism and immunity. Semin Immunol 2012, 24:429-435.
116. Araki K., Ellebedy A.H., Ahmed R. TOR in the immune system. Curr Opin Cell Biol 2011, 23:707-715.
117. Zhang S., Pruitt M., Tran D., Du Bois W., Zhang K., Patel R., et al. B cell-specific deficiencies in mTOR limit humoral immune responses. J Immunol 2013, 191:1692-1703.
118. Berezhnoy A., Castro I., Levay A., Malek T.R., Gilboa E. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest 2014, 124:188-197.
119. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
120. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011, 10:868-880.